Samsung Biologics Secures 97.98% Stake in Polypeptide Tender Offer, Clearing Path for Acquisition
AI 요약 정보
- Samsung Biologics secures 97.98% of Polypeptide
- Samsung plans compulsory buyout to reach 100% ownership
- Close expected by year-end or Q1 2027, pending approvals